Biolevate raised €30 million in Series A funding to expand its workflow automation platform, strengthen products and support international growth.
- Amount
- $34.4M
- Stage
- Series A
- Announced
- 22 September 2026
- Leads
- RAISE France, Orange Ventures
- Other investors
- MSD Global Health Innovation Fund, Station F, EQT Ventures
- Use of funds
- Accelerate international expansion, deepen product capabilities, scale customer deployments, open a Boston office, double the workforce and file patents.
- Checked
- Amount and date matched across 2 press sources